Acceleron Pharma recently presented data on two biomarkers that the company is exploring as part of its strategy to advance personalized drugs for breast and squamous cell head and neck cancer patients.

At the American Society of Clinical Oncology's recent 2012 Markers in Cancer conference, researchers from Acceleron and elsewhere presented data from a study in which patients who had elevated serum levels of the protein activin lived for a shorter time after treatment with Herceptin-containing therapies than those with low levels of the protein.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: the Human Silencing Hub protein complex, and more.

Heads of various research funding agencies discuss how to encourage scientific breakthroughs, ScienceInsider reports.

The Kansas City Star examines issues surrounding newborn genome sequencing.

Researchers say their Research Resource Identifier citation format is catching on, Nature News reports.